ClinicaliQ Trial Snapshot
- Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma — Active Not Recruiting • Phase III • Oncology • NCT04099251.
- Nivolumab immunotherapy reduced melanoma recurrence risk compared to placebo in high-risk patients after surgery.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence. Conditions: Melanoma Interventions: Nivolumab, Placebo Lead Sponsor: Bristol-Myers Squibb Planned Enrollment: 790 participants